Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Q1 2007 Earnings Presentation
20 slides from Novo Nordisk A/s Class B's earnings presentation, May 2, 2007
Slide 1: A focused healthcare company
Conference call 2 May 2007 A focused healthcare company First three months of 2007 conference call 2 May 2007, 13.00 CET, 12.00 UK time, 7.00 New York time
Slide 2: Agenda
Conference call 2 May 2007 First three months of 2007 Slide no 1 Agenda • Introduction (Lars Rebien Sørensen, CEO) • Sales update (Lars Rebien Sørensen, CEO) • Pipeline update (Mads Krogsgaard Thomsen, CSO) • Financial results (Jesper Brandgaard, CFO) • Outlook for 2007 (Jesper Brandgaard, CFO) • Qu
Slide 3: Forward-looking statements
Conference call 2 May 2007 First three months of 2007 Slide no 2 Forward-looking statements The above contains forward-looking statements as the term is defined in the US Private Securities Litigation Reform Act of 1995. This in particular relates to information included under the headings ‘Outlook
Slide 4: Highlights from first three months of 2007
Conference call 2 May 2007 First three months of 2007 Slide no 3 Highlights from first three months of 2007 Market development: • Sales of modern insulins increased by 32% (39% in local currencies) • Sales of NovoSeven® increased by 12% (18% in local currencies) • Sales of Norditropin® increased by
Slide 5: Growth in Novo Nordisk's insulin franchise looks set to continue
Conference call 2 May 2007 First three months of 2007 Slide no 4 Growth in Novo Nordisk’s insulin franchise looks set to continue IMS developed world insulin Rapid increase in number of market growth people with diabetes Volume: 5.4% 200 2007 2025 180 Value: 2007: 246 million 160 10.3% DKK 46.1bn 14
Slide 6: Key products continue to drive growth
Conference call 2 May 2007 First three months of 2007 Slide no 5 Key products continue to drive growth – first three months of 2007 Sales as reported Growth analysis Other Norditropin® +3% Local currencies Growth Share of +11% growth 5% 8% Diabetes care Modern insulins 39% 65% +10% Human insulin and
Slide 7: Modern insulins
Conference call 2 May 2007 First three months of 2007 Slide no 6 Modern insulins Market share of total segment (IMS developed world) Modern insulin sales as reported 40% Levemir® NovoLog® DKK 0.5bn +62% NovoRapid® NovoMix® DKK 1.5bn Levemir® NovoMix® 16% +28% 30% DKK 1.1bn +27% 34% 50% 20% 10% 0% Ja
Slide 8: A continued increase in modern insulin market share
Conference call 2 May 2007 First three months of 2007 Slide no 7 A continued increase in modern insulin market share IMS world modern insulin Modern insulin penetration market shares, volume 80% 70% Novo Nordisk 60% Eli Lilly 49% Modern insulin 50% Sanofi-Aventis 7% 40% 30% Human insulin 20% 10% 0%
Slide 9: NovoSeven sales development
Conference call 2 May 2007 First three months of 2007 Slide no 8 NovoSeven® NovoSeven® sales development Key observations • Growth in the first quarter of 1.600 +12% 18% in local currencies, 12% as reported 1.400 1.200 • North American sales main DKK million contributor to growth 1.000 • Single high
Slide 10: Norditropin sales development and market shares
Conference call 2 May 2007 First three months of 2007 Slide no 9 Norditropin® Norditropin® Global growth hormone sales development market shares, value 60% Pfizer Novo Nordisk +11% Genentech 900 50% Eli Lilly 800 Merck Serono 700 40% DKK million 600 29% 500 30% 22% 400 20% 300 200 10% 100 0 0% Q1 Q1
Slide 11: Sales by region
Conference call 2 May 2007 First three months of 2007 Slide no 10 Sales by region - first three months of 2007 Sales as reported Growth analysis Japan & Oceania -5% Europe Local Growth Share of +11% currencies growth 10% International Europe 11% 27% Operations North America 27% 53% +5% 17% 40% Inter
Slide 12: Levemir reinforces European modern insulin market leadership
Conference call 2 May 2007 First three months of 2007 Slide no 11 Levemir® reinforces European modern insulin market leadership Share of total modern insulin Novo Nordisk’s share of long- sales in Europe acting modern insulin in Europe 22% 60% Novo Nordisk 22% Eli Lilly 20% Sanofi-Aventis 50% 18% 16
Slide 13: US diabetes performance
Conference call 2 May 2007 First three months of 2007 Slide no 12 US diabetes performance Novo Nordisk’s US insulin US insulin market share sales development development Index 80% local currencies 70% Novo Nordisk 500 Eli Lilly 450 60% Sanofi-Aventis 400 % : 38 50% 350 A GR C 300 40% 250 200 30% 150
Slide 14: Development portfolio – diabetes
Conference call 2 May 2007 First three months of 2007 Slide no 13 Development portfolio – diabetes Compound Type Indication Phase Levemir® Modern insulin Types 1+2 Launched in US, Europe, etc. Filed in JP NovoMix® 50 and 70 Modern insulin Types 1+2 Approved in Europe Filed in US Liraglutide GLP-1 an
Slide 15: Development portfolio – haemostasis
Conference call 2 May 2007 First three months of 2007 Slide no 14 Development portfolio – haemostasis Compound Indication Phase NovoSeven® Heat-stable formulation Preparing for filing NovoSeven® Trauma Phase 3 NovoSeven® Prophylaxis Phase 2 completed NovoSeven® Spinal surgery (dose escalation) Phase
Slide 16: Development portfolio - other biopharmaceuticals
Conference call 2 May 2007 First three months of 2007 Slide no 15 Development portfolio - other biopharmaceuticals Compound Indication Phase Activelle® low dose Hormone replacement therapy Launched in the US; Filed in Europe Vagifem® low dose Hormone replacement therapy Phase 3 Norditropin® APCD1 Ph
Slide 17: Financial results
Conference call 2 May 2007 First three months of 2007 Slide no 16 Financial results DKK million Q1 2007 Q1 2006 % change Sales 9,818 8,946 10 Gross profit 7,498 6,531 15 Gross margin 76.4% 73.0% Sales and distribution costs 3,048 2,728 12 Percent of sales 31.0% 30.5% Research and development costs 1
Slide 18: Currency development
Conference call 2 May 2007 First three months of 2007 Slide no 17 Currency development Spot rates Quarterly average Annual average 660 Annual impact on operating profit of a 5% 640 movement in currency 620 USD DKK 400m USD/DKK 600 USD-related DKK 110m JPY DKK 150m 580 GBP DKK 90m 560 USD-related cur
Slide 19: Outlook 2007
Conference call 2 May 2007 First three months of 2007 Slide no 18 Outlook 2007 • Sales growth expectations: • More than 10% in local currencies Key currency rates • Less than 10% as reported DKK 2006 2007 Current • Operating profit growth expectations: per 100 average average rate* • Now more than 1
Slide 20: Investor information
Conference call 2 May 2007 First three months of 2007 Slide no 19 Investor information Share information Investor Relations Novo Nordisk’s B shares are listed contacts on the stock exchanges in Novo Nordisk A/S Investor Relations Copenhagen and London. Its ADRs Novo Allé, DK-2880 Bagsværd are listed